vebreltinib + pemetrexed + platinum-based chemotherapy

This is a combination regimen consisting of **vebreltinib**, **pemetrexed**, and **platinum-based chemotherapy** (with carboplatin or cisplatin) used primarily in clinical trials for **locally advanced or metastatic non-small cell lung cancer (NSCLC)** in patients who have EGFR mutations, MET amplification, and/or overexpression, especially following failure of EGFR tyrosine kinase inhibitor (TKI) therapy. Vebreltinib is a potent and selective inhibitor of the MET tyrosine kinase receptor, targeting tumors with MET dysregulation (such as exon 14 skipping, amplification, or fusion). Pemetrexed is an antimetabolite (antifolate) chemotherapy, and platinum-based chemotherapy involves DNA-damaging agents (cisplatin or carboplatin). This multi-agent regimen is currently under investigation in phase III trials, with vebreltinib aiming to overcome MET-driven resistance mechanisms that can develop after EGFR TKI therapy in NSCLC patients. The regimen is administered intravenously (for pemetrexed and platinum) and orally (for vebreltinib)[1][3].